• Eli Lilly posted a press release disclosing positive topline Phase 3 results for obesity drug candidate retatrutide in TRIUMPH-2, TRIUMPH-3.
• TRIUMPH-2 showed up to 20.8% average weight loss at 80 weeks in adults with obesity or overweight, type 2 diabetes.
• TRIUMPH-3 showed up to 22.6% average weight loss at 80 weeks in severe obesity with established cardiovascular disease.
• FDA Biologics License Application filing targeted for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607230645PR_NEWS_USPR_____DE10479) on July 23, 2026, and is solely responsible for the information contained therein.